TG THERAPEUTICS, INC.TGTXEarnings & Financial Report
TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with B-cell malignancies, autoimmune diseases and neurodegenerative disorders. Its core operating markets are North America and Europe, with key product segments including targeted monoclonal antibodies and oral small molecule treatments.
TGTX Q4 FY2025 Key Financial Metrics
Revenue
$192.6M
Gross Profit
$154.4M
Operating Profit
$50.5M
Net Profit
$23.0M
Gross Margin
80.2%
Operating Margin
26.2%
Net Margin
12.0%
YoY Growth
78.0%
EPS
$0.14
TG THERAPEUTICS, INC. Q4 FY2025 Financial Summary
TG THERAPEUTICS, INC. reported revenue of $192.6M (up 78.0% YoY) for Q4 FY2025, with a net profit of $23.0M (down 1.3% YoY) (12.0% margin). Cost of goods sold was $38.1M, operating expenses totaled $103.9M.
Key Financial Metrics
| Total Revenue | $192.6M |
|---|---|
| Net Profit | $23.0M |
| Gross Margin | 80.2% |
| Operating Margin | 26.2% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
TG THERAPEUTICS, INC. Q4 FY2025 revenue of $192.6M breaks down across 2 segments, led by Products at $189.1M (98.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $189.1M | 98.2% |
| License | $3.5M | 1.8% |
TG THERAPEUTICS, INC. Revenue by Segment — Quarterly Trend
TG THERAPEUTICS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and License) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | $189.1M | $159.3M | $138.8M | $119.7M |
| License | $3.5M | — | — | $1.2M |
TG THERAPEUTICS, INC. Annual Revenue by Year
TG THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $616.3M).
TG THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
TG THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $192.6M | +78.0% | $23.0M | 12.0% |
| Q3 FY2025 | $161.7M | +92.8% | $390.9M | 241.7% |
| Q2 FY2025 | $141.1M | +92.1% | $28.2M | 20.0% |
| Q1 FY2025 | $120.9M | +90.4% | $5.1M | 4.2% |
| Q4 FY2024 | $108.2M | +146.0% | $23.3M | 21.6% |
| Q3 FY2024 | $83.9M | -49.4% | $3.9M | 4.6% |
| Q2 FY2024 | $73.5M | +357.0% | $6.9M | 9.4% |
| Q1 FY2024 | $63.5M | +713.5% | $-10.7M | -16.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.5M | $73.5M | $83.9M | $108.2M | $120.9M | $141.1M | $161.7M | $192.6M |
| YoY Growth | 713.5% | 357.0% | -49.4% | 146.0% | 90.4% | 92.1% | 92.8% | 78.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $373.3M | $401.2M | $586.0M | $577.7M | $656.7M | $702.6M | $1.03B | $1.06B |
| Liabilities | $213.2M | $223.6M | $393.9M | $355.3M | $419.4M | $426.2M | $417.8M | $415.2M |
| Equity | $160.1M | $177.6M | $192.2M | $222.4M | $237.3M | $276.4M | $607.2M | $648.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.2M | $5.5M | $-12.2M | $-25.6M | $-28.7M | $7.4M | $-23.2M | $19.7M |